<!--
;;;***************************************************************************
;;;* Copyright 2017 by Cancer Commons                                        *
;;;*                                                                         *
;;;* Permission is hereby granted, free of charge, to any person obtaining   *
;;;* a copy of this software and associated documentation files (the         *
;;;* "Software"), to deal in the Software without restriction, including     *
;;;* without limitation the rights to use, copy, modify, merge, publish,     *
;;;* distribute, sublicense, and/or sell copies of the Software, and to      *
;;;* permit persons to whom the Software is furnished to do so, subject to   *
;;;* the following conditions:                                               *
;;;*                                                                         *
;;;* The above copyright notice and this permission notice shall be          *
;;;* included in all copies or substantial portions of the Software.         *
;;;*                                                                         *
;;;* THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND,         *
;;;* EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF      *
;;;* MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND                   *
;;;* NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE  *
;;;* LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION  *
;;;* OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION   *
;;;* WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.         *
;;;***************************************************************************
-->
<head><title>Cancer Commons Knowledge Pipeline API documentation</title></head>
<h1>Cancer Commons Knowledge Pipeline API documentation</h1>
<br>
<h2>Controlled Natural Lanuage Parser</h2>

The Controlled Natural Lanuage (CNL) parser turns treatment rationales
(TRs) composed in JSON semtantic structures. It accepts a wide range
of "standardized" forms, <a target=_blank href=testnlp.html>as
exemplified here</a> and returns JSON, as below.

<pre>
<a target=_blank href=http://platformtest.cancercommons.org:4242/cnlparser?s=In+a+randomized+controlled+trial+involving+100+patients+with+stage+2+metastatic+lung+cancer+%28shrager%2C+1998%29%2C+EGFR+expression+confers+sensitivity+to+dexamethasone.>http://platformtest.cancercommons.org:4242/cnlparser?s=In+a+randomized+controlled+trial+involving+100+patients+with+stage+2+metastatic+lung+cancer+%28shrager%2C+1998%29%2C+EGFR+expression+confers+sensitivity+to+dexamethasone.</a>

-> 


      {"cancer":["stage",2,"metastatic","CANCERTYPE.LUNG","cancer"],
      "relation":"sensitivity_to",
      "adverse event":null,
      "reference":"shrager, 1998",
      "molecule(s)":[{"name":"M.EGFR","state":"MUTYPEWORD.EXPRESSION"}],
      "model":"rct",
      "cases":100,
      "drug(s)":["DEXAMETHASONE"]
      }
      
</pre>

<a target=_blank href=ocip1.txt>Documentation regarding CNL can be found here.</a>
<p>
If the parse fails, an array is returned with proposed spelling corrections, for example:
<pre>

<a target=_blank href=http://platformtest.cancercommons.org:4242/cnlparser?s=In+a+ranomized+controled+trial+invoving+100+patents+with+stage+2+metstatic+lugn+cacner+%28shrager%2C+1998%29%2C+EGFR+experssion+confers+sensiitvity+to+dexmaethsaon.>http://platformtest.cancercommons.org:4242/cnlparser?s=In+a+ranomized+controled+trial+invoving+100+patents+with+stage+2+metstatic+lugn+cacner+%28shrager%2C+1998%29%2C+EGFR+experssion+confers+sensiitvity+to+dexmaethsaon.</a>

-> 

[
  "_PARSEFAILED_PROPOSED_SPELLING_CORRECTIONS_",
  {
    "ranomized": "randomized",
    "controled": "controlled",
    "invoving": "involving",
    "patents": "patients",
    "metstatic": "metastatic",
    "lugn": "slug",
    "cacner": "dacarbazine-+-quercetin",
    "experssion": "expression",
    "sensiitvity": "sensitivity",
    "dexmaethsaon": "dexamethasone"
  }
]

</pre>
<hr>
<h2>NCI Thesaurus Ontology Lookup Services</h2>

We use the <a target=_blank
href=https://ncit.nci.nih.gov/ncitbrowser/>NCI Thesaurus</a> as our
standardized ontology. The ncit api looks up either names or NCIT IDs,
returning a JSON record extracted from the TXT version of the
Thesaurus. For example:

<pre>


<a target=_blank href=http://platformtest.cancercommons.org:4241/ncit?name=sorafenib>http://platformtest.cancercommons.org:4241/ncit?name=sorafenib</a>

-> 

[
  {
    "cid": "C2194",
    "type": "ORGANIC_CHEMICAL",
    "isas": [
      "c1404"
    ],
    "names": [
      "Sorafenib Tosylate",
      "4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic Acid Methyamide-4-methylbenzenesulfonate Tosylate",
      "BAY 43-9006 Tosylate",
      "BAY 54-9085",
      "Nexavar",
      "SORAFENIB TOSYLATE",
      "sorafenib",
      "sorafenib tosylate"
    ]
  },
  {
    "cid": "C61948",
    "type": "PHARMACOLOGIC_SUBSTANCE",
    "isas": [
      "c1404"
    ],
    "names": [
      "Sorafenib",
      "BAY 43-9006",
      "SORAFENIB",
      "sorafenib"
    ]
  }
]

<a target=_blank href=http://platformtest.cancercommons.org:4241/ncit?name=C61948>http://platformtest.cancercommons.org:4241/ncit?name=C61948</a>

->

[
  {
    "cid": "C61948",
    "type": "PHARMACOLOGIC_SUBSTANCE",
    "isas": [
      "c1404"
    ],
    "names": [
      "Sorafenib",
      "BAY 43-9006",
      "SORAFENIB",
      "sorafenib"
    ]
  }
]

</pre>
<hr>

<h2>TrEx -- The Treatment Explorer</h2>

TrEx, The "Treatment Explorer", accepts observations and statistically
ranks plausaible treatments in accord with these observations. There
is an interact mode that is used to test TrEx, and which can be used
for demos, although it is not very pretty. This mode is reached as follows:

<pre>

<a target=_blank href=http://platformtest.cancercommons.org:4240/trexui>http://platformtest.cancercommons.org:4240/trexui</a>

->

Runs TrEx in interactive test/demo mode.

</pre>

Before using the TrEx Ranking API you must find the test and drug keys, which
are numbers associated with each test and drug. Use this API for that:

<pre>

<a target=_blank href=http://platformtest.cancercommons.org:4240/trexkeys>http://platformtest.cancercommons.org:4240/trexkeys</a>

-> 

{
  "tests": {
    "1": "MITF amplified (gene)",
    "2": "KIT mut V560A (exon 11)",
    "3": "BRAF, CRAF, VEGFR, PDGFR expressed",
    "4": "MGMT expressed",
    "5": "MLH1 expressed",
    "6": "MLH2 expressed",
    "7": "MSH2 polymorphism rs2303428",
    "8": "KIT mut L576P (exon 11)",
    "9": "CRAF expressed",
    "10": "ERK phosphorylated (activated)",
    "11": "BRAF mut D595G",
    "12": "BRAF mut G469E",
    "13": "BRAF mut V600E",
    "14": "IL-8 expressed",
    "15": "VEGF expressed"
    ...
  },
  "drugs": {
    "1": "BI-69A11",
    "2": "SOCS1 gene therapy",
    "3": "4-Methylumbelliferone",
    "4": "ADAM10",
    "5": "GLI1 siRNA",
    "6": "Siomycin A",
    "7": "Epoxomicin",
    "8": "Menadione",
    "9": "IKK inhibitor",
    ...
  }
}
</pre>

Next, call the trexrank API using the test keys, as above, and assigning +1, 0, or -1 to each test. <em>It is extremely important to understand what these numbers mean. Refer to the interactive mode documention for an explanation.</em>

<pre>

<a target=_blank href=http://platformtest.cancercommons.org:4240/trexrank?observations=[[1,1],[2,-1],[3,1],[4,-1],[5,0],[6,0],[7,0],[8,0],[9,0],[10,0],[11,0],[12,0],[13,0],[14,0],[15,0]]>http://platformtest.cancercommons.org:4240/trexrank?observations=[[1,1],[2,-1],[3,1],[4,-1],[5,0],[6,0],[7,0],[8,0],[9,0],[10,0],[11,0],[12,0],[13,0],[14,0],[15,0]]</a>

-> 

[
  {
    "drug": "Dacarbazine based chemotherapy",
    "overallscore": 1,
    "standard-error": 0.0018159464,
    "variance": 3.2976616e-6,
    "ci-upper": 1.0035592,
    "ci-lower": 0.99644077,
    "p": 0,
    "z": 275.33853
  },
  {
    "drug": "6-thioguanine",
    "overallscore": 1,
    "standard-error": 0.048031278,
    "variance": 0.0023070038,
    "ci-upper": 1.0941412,
    "ci-lower": 0.9058587,
    "p": 0,
    "z": 10.4098835
  },
  {
    "drug": "Imatinib",
    "overallscore": 0,
    "standard-error": 0.0727834,
    "variance": 0.0052974243,
    "ci-upper": 0.14265548,
    "ci-lower": -0.14265548,
    "p": 6.4337424277028e-12,
    "z": -6.869698
  },
  {
    "drug": "Bevacizumab",
    "overallscore": 0,
    "standard-error": 0.05446327,
    "variance": 0.002966248,
    "ci-upper": 0.106748015,
    "ci-lower": -0.106748015,
    "p": 0,
    "z": -9.180499
  },
</pre>

It is often useful to be able to see the evidence underlying TrEx's
ranking algorithm. You can use this API for this purpose:

<pre>


<a target=_blank href=http://platformtest.cancercommons.org:4240/trexev?key=braf%20v600e>http://platformtest.cancercommons.org:4240/trexev?key=braf%20v600e</a>

->

[
  [
    {
      "_id": "TTD-1",
      "cancer": "Melanoma",
      "Alias (modifier)": "",
      "relation": "efficacy",
      "reference": "Da Rocha Dias S, Cancer Res 2005, 65:10686-91",
      "note": "17-AAG is a HSP90 inhibitor",
      "molecule": {
        "state": "mut V600E",
        "name": "BRAF",
        "class": "DNA"
      },
      "hypothesis": {
        "condition": "BRAF mut V600E",
        "relation": "efficacy",
        "cancer": "Melanoma",
        "drug": "17-AAG"
      },
      "Modifier": "",
      "model": 3,
      "condition": "BRAF mut V600E",
      "collaborations": [
        "TTD"
      ],
      "h": 1,
      "drug": "17-AAG",
      "insightLabel": "TTD-1",
      "relationshipTo": "sensitivity to",
      "ref_url": "https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16322212"
    },
    {
      "_id": "TTD-1062",
      "cancer": "Melanoma",
      "Alias (modifier)": "",
      "relation": "efficacy",
      "reference": "Wajapeyee N, Mol Cancer Ther 2009, 8:3009-14",
      "note": "In human melanomas containing an activating BRAF mutation (BRAF-positive melanomas), IGFBP7 is epigenetically silenced, which seems to be a critical step in melanoma genesis. Restoration of IGFBP7 function by the administration of recombinant IGFBP7 induces apoptosis in BRAF-positive human melanoma cell lines suppresses the growth of BRAF-positive primary tumors in xenografted mice",
      "molecule": {
        "state": "mut V600E",
        "name": "BRAF",
        "class": "DNA"
      },
      "hypothesis": {
        "condition": "BRAF mut V600E",
        "relation": "efficacy",
        "cancer": "Melanoma",
        "drug": "IGFBP7"
      },
      "Modifier": "",
      "model": 4,
      "condition": "BRAF mut V600E",
      "collaborations": [
        "TTD"
      ],
      "h": 1,
      "drug": "IGFBP7",
      "insightLabel": "TTD-1062",
      "relationshipTo": "sensitivity to",
      "ref_url": "https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19861408"
    },
...
  ],
  null
]
</pre>
